

JUL 25 2006

VIA FACSIMILE

Attorney Dkt. No. 51275/148

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: application of:
Theoharis C. Theoharides
Filing date: 03/30/2004
Serial No.: 10/811,826

Group Art Unit: 1655
Examiner: Patricia A. Leith

Priority from copending PCT/US02/00476, filed 01/03/2002,
copending USSN 09/771,669, filed 01/30/2001, and USSN 09/056,707, filed
4/8/1998, now USPN 6,689,748, issued 2/10/2004
For: Anti-Inflammatory Compositions for Multiple Sclerosis

Response to Office Action (Notice of Non-Compliant Amendment)

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450
Mail Stop:Non-Fee Amendment

Sir:

In response to the Office Action mailed 06/30/2006 by LIE Patterson,
requiring a separate list of claim status, such a list is attached..

Respectfully submitted,



Dr. Melvin Blecher
Attorney-at-Law
Registration No. 33,649

Date of signature: 07/25/2006

Law Offices of Dr. Melvin Blecher
4329 Van Ness St., NW
Washington, DC 20016-5625
Tel: 202 363 3338
FAX: 202 362 8404
e-mail: MBIplaw@comcast.net

RECEIVED
CENTRAL FAX CENTER

JUL 25 2006

Current Claim Status

40. (Original) A composition for protecting a subject from the inflammatory components of multiple sclerosis, said composition comprising non-bovine chondroitin sulfate, quercetin or myricetin, hydroxyzine, and, optionally, olive kernel extract, in a vehicle for oral administration.
41. (Currently amended) The composition of claim 40 contained in one part of a kit, wherein a second part of said kit contains an injectable form of interferon-beta for optional administration.
42. (Currently amended) The composition according to claim 40, wherein said composition comprises, in mg/day, 50-300 each of non-bovine chondroitin sulfate, quercetin or myricetin, hydroxyzine, and optionally 150-600 of olive kernel extract, in a vehicle for oral administration.
43. (Currently amended) The composition of claim 42 further comprising injecting 8 million IU interferon-beta on alternate days or 30 µg i.m. once weekly.
44. (Original) A method of protecting multiple sclerosis patients against brain inflammatory processes, comprising the administration to said patients of the composition of claim 40.
45. (Currently amended) A method of protecting multiple sclerosis patients against brain inflammatory processes, comprising the administration to said patients of the composition of claim 41.